Scores (norm)* | Subjects with Gilbert Syndrome) (101 subjects; n = 83 with GS and 18 with GS and treated HCV) | Control subjects (n = 100) | P value | ||
---|---|---|---|---|---|
During jaundice episode | In between jaundice episodes | During jaundice episode | In between jaundice episodes | ||
SF-6D preference | 0.72 ± 0.12 | 0.77 ± 0.12 | 0. ± 0.11 | < 0.0001** | 0.278 |
SF-36v2 | |||||
PF | 82.5 ± 7.35 | 89.952 ± 2.41 | 90.10 ± 2.40 | 0.0001** | 0.051 |
RP | 90.19 ± 4.2 | 89.19 ± 4.2 | 90. ± 1.4 | 0.06 | 0.81 |
BP | 81.3 ± 3.5 | 83.03 ± 2.8 | 82.63 ± 6.36 | 0.07 | 0.56 |
GH | 49.27 ± 14.5 | 52.64 ± 10.3 | 53.24 ± 9.11 | 0.02 * | 0.66 |
VT | 55.34 ± 4.61 | 59.81 ± 4.18 | 60.35 ± 3.617 | 0.0001** | 0.33 |
SF | 87.16 ± 9.73 | 92.74 ± 15.2 | 92.47 ± 14.9 | 0.0031** | 0.9 |
RE | 80.61 ± 7.24 | 88.39 ± 5.21 | 88.53 ± 8.56 | < 0.0001** | 0.88 |
MH | 71.9 ± 3.6 | 72.6 ± 3.04 | 72.10 ± 4.3 | 0.38 | 0.71 |
PCS | 45.00 ± 12.9 | 47.927 ± 9.21 | 48.81 ± 8.7 | 0.02 | 0.48 |
MCS | 49.81 ± 3.9 | 49.71 ± 3.82 | 50.87 ± 4.31 | 0.07 | 0.07 |
CLDQ | |||||
AS | 5.48 ± 1.83 | 6.2 ± 1.64 | 6.23 ± 1.55 | 0.012* | 0.58 |
FA | 4.80 ± 1.25 | 5.37 ± 1.36 | 5.72 ± 1.03 | < 0.0001** | 0.04* |
SS | 5.02 ± 0.82 | 5.712 ± 1.224 | 5.82 ± 1.0 | < 0.0001 ** | 0.47 |
AC | 5.87 ± 1.84 | 6.25 ± 1.33 | 6.55 ± 1.41 | 0.004 ** | 0.12 |
EF | 5.231 ± 1.74 | 5.73 ± 1.41 | 5.84 ± 1.43 | 0.007 * | 0.59 |
WO | 5.41 ± 1.26 | 5.83 ± 1.54 | 5.90 ± 1.632 | 0.02* | 0.72 |
Overall | 5.32 ± 1.36 | 5.82 ± 0.89 | 5.92 ± 1.63 | 0.006** | 0.64 |